Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alphacypermethrin
- Development stage
- Unknown
- Lead developer
- FMC Corporation
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Alphacypermethrin is a highly active, broad-spectrum synthetic Type II pyrethroid insecticide and veterinary ectoparasiticide. It is a stereoisomeric mixture consisting of the two most biologically active cis-isomers of cypermethrin: (1R,cis)-alpha-S and (1S,cis)-alpha-R. Alphacypermethrin acts by binding to voltage-gated sodium channels (VGSCs) in the nerve membranes of target pests, delaying channel closure and causing prolonged sodium influx, which leads to hyperexcitation, paralysis, and death. It is widely used in agriculture, public health (such as on insecticide-treated mosquito nets for malaria vector control), and veterinary medicine to treat and prevent ectoparasitic infestations (including ticks, lice, fleas, and mites) in livestock and companion animals.
- Brand names
- AlfasectAlfathrinAlfazotAlphaguardAlphakillAlphamethrateAlpharinAlphatoxAlpineAstoundBalaBestoxBestsellerBonsulClameurConcordContestDominexDysectEfitaxFastacFendonaHilalphaHurricaneMageosMagicPilar-AlfaPrabalRenegade
- Other names
- alfamethrinalfoxylatealpha-cypermethrinalphamethrin
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on alphacypermethrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alphacypermethrin.